Relay Therapeutics (RLAY) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

RLAY Relay Therapeutics

Watchlist

3.410
+0.160+4.92%

Close Feb 28 16:00 ET

3.400
-0.010-0.29%

Post 20:01 ET

578.07MMarket Cap-1.44P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $12
Moomoo NewsMar 1 06:31 ET · Ratings
BofA Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $19
Moomoo NewsFeb 28 08:31 ET · Ratings
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $12 to $23
Moomoo NewsFeb 28 08:00 ET · Ratings
Relay Therapeutics Price Target Lowered to $12 From $21 at Citizens JMP
TipRanksFeb 28 07:06 ET
Relay Therapeutics Is Maintained at Buy by Goldman Sachs
Dow JonesFeb 27 12:14 ET · Ratings
Relay Therapeutics Is Maintained at Buy by Stifel
Dow JonesFeb 27 10:47 ET · Ratings

Comments

joeyboulevard

Jan 10 17:15

$Relay Therapeutics (RLAY.US)$ here for 2025.

Jaguar8

Dec 11, 2024 05:03

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Relay Therapeutics (RLAY) announced updated interim data for RLY-2608, showing an 11.4-month median progression-free survival in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at the recommended Phase 2 dose. The study demonstrated a 39% confirmed objective response rate ...

Trytosaveabit

Dec 11, 2024 05:01

Update

$Relay Therapeutics (RLAY.US)$ Reuters· just
Relay Therapeutics Announces Updated Interim Data for Rly-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Jaguar8

Dec 9, 2024 15:07

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Relay Therapeutics (RLAY) announced it will present updated clinical data for RLY-2608 in combination with fulvestrant for treating PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer at the San Antonio Breast Cancer Symposium (December 10-13, 2024). The presentation, titled 'Efficacy of RLY-2608, a mutant-se...

Jaguar8

Dec 3, 2024 16:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

Trending Stocks

Symbol Mini Chart % Chg

Unlock the Full List